CHENGDA PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 16.7733 million yuan, a decrease of 58.47%
I'm LongbridgeAI, I can summarize articles.CHENGDA PHARMA released its third-quarter report for 2025, with operating revenue of 285 million yuan in the first three quarters, a year-on-year increase of 16.95%. The net profit attributable to the parent company was 16.7733 million yuan, a year-on-year decrease of 58.47%; the net profit after deducting non-recurring gains and losses was 3.9025 million yuan, a year-on-year decrease of 72.96%. The basic earnings per share were 0.1107 yuan
According to the Zhitong Finance APP, CHENGDA PHARMA (301201.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 285 million yuan, a year-on-year increase of 16.95%. The net profit attributable to shareholders of the listed company was 16.7733 million yuan, a year-on-year decrease of 58.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.9025 million yuan, a year-on-year decrease of 72.96%. The basic earnings per share were 0.1107 yuan